Genome-wide RNAi library with cellular screening system

Xantos Biomedicine AG and Qiagen have announced their partnership for co-marketing Qiagen's proprietary TOM-amidite chemistry-based genome-wide RNAi products with Xantos' automated cell-based screening platform, XantoScreen. By combining the capabilities of both companies' platforms users will be able to rapidly perform gene analysis and unravel the function and role of genes that are relevant to their area of interest.

Xantos provides XantoScreen for the discovery and functional validation of novel targets on a genome-wide basis. The system enables high throughput and automated cDNA transfection studies (over expression of genes) or RNAi (gene silencing) to be carried out rapidly. This system can be customised to a range of high content cellular screening assays and enables individual cDNAs, RNAi molecules or proteins to be studied in combination with or without inhibitory molecules, to identify and validate targets, ligands, receptors, compounds or pathways.

Qiagen is a supplier of validated siRNA libraries. It employs its TOM-amidites chemistry to produce High Performance Purity grade siRNA for efficient gene silencing. As a licensed supplier of siRNA, Qiagen offers pre-designed, genome-wide siRNA molecules. Qiagen's siRNA products combined with its RNA transfection, purification and detection technologies provide a fully integrated solution for ultra high-throughput gene silencing.